Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Vasculitis 1Prostatic Neoplasms 1Neoplasms 1Lupus Erythematosus, Systemic 1Leukemia, Myeloid, Acute 1Glomerulonephritis 1COVID-19 1

Interventions

pembrolizumab 603Cyclophosphamide 545Magnetic Resonance Spectroscopy 527Radiotherapy 513Specimen Handling 505Nivolumab 411Cisplatin 381Carboplatin 369Biopsy 305Blood Specimen Collection 304Radiosurgery 290Paclitaxel 281Gemcitabine 271Surveys and Questionnaires 269Standard of Care 267fludarabine 263Drug Therapy 263Dexamethasone 263Bevacizumab 252venetoclax 251Oxaliplatin 209Capecitabine 199Rituximab 198Radiation 191Ipilimumab 188Fluorouracil 188durvalumab 185Doxorubicin 178Etoposide 177atezolizumab 172

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Niclosamide × 1 year × Clear all
NCT03123978 2026-05-06

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

University of California, Davis

Phase 1 Completed
6 enrolled
Genitourinary

Prostatic Neoplasms

NCT05188170 2026-01-12

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Stanford University

Phase 1 Recruiting
16 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed
2,240 enrolled

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡